Seattle Genetics is a globally recognized biotech firm specializing in drugs specifically designed to target certain diseases that has a low mortality rate. This innovative firm is led by its founder Clay Siegall.
In a recent interview, Mr. Siegall said that two personal quests have prompted him to create a boutique style of curing diseases like cancer. The first driving force was his own innate desire to use technology to beat diseases and restore the health of individuals whose prognosis was death. Secondly, he vowed to be monetarily successful, but just to be able to research and test without any outside restrictions.
Today, Dr. Siegal stated that Seattle Genetics makes lucrative monies by selling their own dominion drugs and receiving substantial revenues from manufacturing partnerships and the licensing of technologies and procedures that Seattle Genetics has developed.
Under Siegal’s leadership, Seattle Genetics has already developed many successful drugs to expand the life of people. This advanced research development helps to make the firm a leader in the drug development industry.
Dr. Siegall graduated from The University of Maryland with a Bachelor of Science in zoology. He also received a Ph.D. in genetics from George Washington University. It was his studies in zoology that initially got him interested in cancer and their treatments.
While in school a close family member was diagnosed with cancer but suffered through their treatment and even developed anemia, nearly dying. Witnessing the suffering of his family member he knew that there just had to be a better treatment.
When asked the key to his success, Dr. Siegall equivocally said that hard work should be taken for granted. Also, having passion for what you do helps you to work even harder. Following these traits is having a good IQ, attending an excellent educational institution and people who have helped along the way.
Clay Siegall has taken a small neophyte company to a global research and drug development firm whose reputation proceeds itself in the field of cancer research. Dr. Siegall further stated that he has futuristic plans for the continued growth of Seattle Genetics.